Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Taxus Cardium Pharmaceuticals Group, Inc. (OTC: CRXM).

Full DD Report for CRXM

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-120.062390.06590.06590.0623,510
2018-12-110.06250.0660.066950.0623,789
2018-12-10N/A0.06695N/AN/A0
2018-12-070.0620.066950.066950.0622,730
2018-12-060.06250.066950.066950.0628,008

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-063,3338,00841.6209Short
2018-12-045003,35714.8943Cover
2018-11-281,0005,75117.3883Cover
2018-11-277,50018,32040.9389Short
2018-11-269,18126,90634.1225Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CRXM.


About Taxus Cardium Pharmaceuticals Group, Inc. (OTC: CRXM)

Logo for Taxus Cardium Pharmaceuticals Group, Inc. (OTC: CRXM)

Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium s current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company s in house MedPodium Health Sciences healthy lifestyle product platform. The Company s lead commercial product Excellagen R topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium s lead clinical development product candidate Generx R is a DNA based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July , Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company s biomedical investment portfolio.

 

 

 

Current Management

  • Christopher Reinhard / President, CEO
  • Tracy Kent / Business Affairs, Executive Director
  • Mira Habel / Corporate Controller
  • Bonnie Ortega / IR
  • Christopher Reinhard / Chairman

Current Share Structure

  • Market Cap: $1,367,862 - 03/15/2018
  • Authorized: 200,000,000 - 03/14/2018
  • Issue and Outstanding: 14,398,544 - 03/14/2018

 


Recent Filings from (OTC: CRXM)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 09 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 04 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2017

 

 


Daily Technical Chart for (OTC: CRXM)

Daily Technical Chart for (OTC: CRXM)


Stay tuned for daily updates and more on (OTC: CRXM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CRXM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CRXM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CRXM and does not buy, sell, or trade any shares of CRXM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/